XOMA Royalty Corporation Announces Preferred Stock Dividends

Quarterly Preferred Stock Dividend Announcement by XOMA Royalty

XOMA Royalty Corporation today revealed exciting news for its stakeholders regarding the upcoming quarterly dividends for preferred stock holders. This pronouncement highlights the financial health and innovative drive of XOMA as a key player in the biotechnology sector, particularly focusing on developing therapies that can enhance human health.

Details of the Dividends Declared

The company's Board of Directors has officially declared cash dividends that will significantly benefit holders of its Series A and Series B cumulative preferred stock. Investors holding the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive a cash dividend of $0.53906 per share. This demonstrates the company's commitment to returning value to its shareholders.

Additionally, holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will enjoy a cash dividend of $0.52344 for each depositary share they hold. This announcement reinforces XOMA’s dedication to providing continuous support to its investors through reliable dividend payments.

Payment Schedule and Conditions

The preferred stock dividends are scheduled for payment around January 15, 2025, with eligibility for holders who are on record by the close of business on January 3, 2025. This clear timeline gives shareholders confidence in their investment and anticipates their financial returns in the coming months.

XOMA Royalty Corporation’s Business Model

XOMA Royalty operates as a biotechnology royalty aggregator, playing a unique role in assisting biotech firms with their aspirations to enhance human health outcomes. The company excels in acquiring potential future economics linked to pre-commercial therapeutic candidates that have already been licensed to various pharmaceutical or biotech companies.

When a company partners with XOMA Royalty, they have the opportunity to secure non-dilutive and non-recourse funding. This capital can be instrumental for these companies, allowing them to either advance their internal drug development efforts or support other essential corporate initiatives. The extensive portfolio maintained by XOMA encompasses numerous assets, defined as the rights to receive future economic benefits from the progress of the underlying therapeutic candidates.

Overview of Current Therapeutic Assets

XOMA Royalty boasts a diverse portfolio comprised of several notable commercial assets and investigational compounds. Among the established assets is VABYSMO® (faricimab-svoa), a product designed for treating specific eye conditions. Additionally, the portfolio includes OJEMDA™ (tovorafenib) and MIPLYFFA™ (arimoclomol), which are focused on oncology and infectious diseases, respectively.

XOMA also has rights to XACIATO™ (clindamycin phosphate) vaginal gel, IXINITY® (coagulation factor IX, recombinant), and DSUVIA® (sufentanil sublingual tablet). Collectively, these assets highlight the company’s vigorous role in the biotechnology landscape. Nonetheless, many assets currently remain investigational, emphasizing that while there is significant potential, the effectiveness and safety of these compounds have yet to be fully established.

Commitment to Investors

XOMA Royalty Corporation's dividends announcement showcases not only its sound financial practices but also its comprehensive approach to supporting innovative biotech projects. The corporation continues to actively manage its growing portfolio with the intent to provide shareholder value while fostering the advancement of therapeutic innovations.

Frequently Asked Questions

What are the announced dividends for XOMA stockholders?

The 8.625% Series A Cumulative Perpetual Preferred Stock holders will receive $0.53906 per share, while the 8.375% Series B Cumulative Perpetual Preferred Stock holders will receive $0.52344 per depositary share.

When will the dividends be paid?

Dividends are expected to be paid on or about January 15, 2025, to eligible stockholders.

Who can receive the dividends?

Stockholders who are on record as of the close of business on January 3, 2025, will be eligible to receive the dividends.

What is XOMA Royalty Corporation's main business focus?

XOMA Royalty focuses on acquiring future economic rights in pre-commercial therapeutic candidates, providing funding for biotech companies to support their drug development.

What are some assets in XOMA's portfolio?

Current assets include VABYSMO®, OJEMDA™, MIPLYFFA™, and XACIATO™, among others, with a mixture of commercial and investigational compounds.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.